Previous 10 | Next 10 |
WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today ...
Bellerophon Therapeutics (NASDAQ: BLPH ) : Q2 GAAP EPS of -$0.51 beats by $0.21 . Cash and cash equivalents of $59.3M. Press Release More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a...
Galera Therapeutics Advances Mid Stage Clinical Trial of GC4419 Galera Therapeutics Inc. ( GRTX ) reported that it has completed the process of patient enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. The drug candidate is being assessed for safety and ant...
Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16 th , from 4:00-5:00 pm EDT WARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a cli...
Bellerophon Therapeutics ( BLPH +4.8% ) announces that the first patient has initiated treatment in Phase 3 study of INOpulse inhaled nitric oxide therapy for COVID-19. More news on: Bellerophon Therapeutics, Inc., Healthcare stocks news, Read more ...
WARREN, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has initiated treatment in the Company...
Orgenesis (NASDAQ: ORGS ) added to the Russell 3000 Index, effective after the market open June 29 . More news on: Orgenesis Inc., Soleno Therapeutics, Inc., Cidara Therapeutics, Inc., Healthcare stocks news, Read more ...
WARREN, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000 ...
WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering and concurrent registered direct offering (the “Offerings&...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...